Bjorn Van Campenhout -
ID: UNCST-2020-R014080
|
Demand and supply factors constraining the emergence and sustainability of an efficient seed system in Uganda.
REFNo: SS603ES
The proposed study aims to provide innovative, evidence-based insights on the:
i. Mechanisms that encourage more efficient marketing and distribution of seed and traits at various levels of commercialization and across heterogeneous populations and agro-ecologies (“improving seed supply”), and;
ii. Mechanisms that nudge farmers—youth, women, and smallholders—into using improved varieties and quality seed, including varieties and seed for climate-smart and nutrient-dense crops and traits (“enhancing seed demand”).
|
Belgium |
2020-09-23 |
2023-09-23 |
Social Science and Humanities |
|
Non-degree Award |
|
Charles Drago Kato Drago
ID: UNCST-2021-R012897
|
Clinical evaluation of novel plasma biomarkers for stage diagnosis among sleeping sickness patients in Uganda
REFNo: HS520ES
1. To identify plasma biomarkers associated with either early or late stage T. b. gambiense disease using proteomics methods and compare with those previously identified for T. b. rhodesiense.
2. To determine the potential of plasma biomarkers identified using proteomics methods in discriminating between early and late stage patients for both T. b. rhodesiense and T. b. gambiense sleeping sickness.
3. To initiate the setup of a biomarker research team and laboratory at Makerere University.
|
Uganda |
2020-09-18 |
2023-09-18 |
Medical and Health Sciences |
|
Non-degree Award |
.JPG)
|
Sarah Nanzigu
ID:
|
Effects of Co-administration of HAART and Antiepileptic drugs on pharmacokinetics, seizure control and ART outcomes among Ugandans aged 0-24 years.
Short title: Study of Co-medication with HAART and antiEpileptic Drugs
Acronym: Co-HED
REFNo: HS546ES
General Study Objective: To evaluate the pharmacokinetics and clinical effects of HIV and antiepileptic co-medication among Ugandan patients aged 0-24 years.
SUB-STUDY I
This will be a cross-sectional, evaluating short and long-term effects of HAART-AED co-medication on the pharmacokinetics and treatment outcomes of HAART among Ugandans aged 0-24 years.
Specific objectives for sub-study 1
The specific objectives to be addressed during this sub-study will include the following:
1. To determine the effect of combined treatment with HAART and antiepileptic agents on virological control among HIV infected Ugandans aged 0-24 years, attending Baylor HIV clinic.
2. To determine the effect of combined treatment with HAART and antiepileptic agents on the immunological outcomes of HIV infected Ugandans aged 0-24 years, attending Baylor HIV clinic.
3. To determine the effect of combined treatment with HAART and antiepileptic agents on the safety of Ugandans aged 0-24 years, attending Baylor HIV clinic.
The study shall as well address secondary objectives that include the following:
1. To determine the effect of combined treatment with HAART and antiepileptic agents on efavirenz plasma concentrations, among HIV infected Ugandans aged 0-24 years attending Baylor HIV clinic.
2. To determine the effect of combined treatment with HAART and antiepileptic agents on lopinavir plasma concentrations, among Ugandans aged 0-24 years attending Baylor HIV clinic.
SUB-STUDY II
The main objective of this sub-study will be to evaluate the effect of HAART on the pharmacokinetics and clinical outcomes of carbamazepine and sodium valproate among Ugandans aged 0-24 years during 6 months of combined treatments for HIV and epileptic conditions.
Specific Objectives for sub-study II
1. To determine the effect of HAART on the pharmacokinetics of carbamazepine among Ugandans aged 0-24 years, during 6 months of combined treatment for HIV and epilepsy
2. To determine the effect of HAART on the pharmacokinetics of sodium valproate among Ugandans aged 0-24 years, during 6 months of combined treatment for HIV and epilepsy
3. To determine the effect of HAART on seizure control among Ugandans aged 0-24 years, during 6 months of combined treatment for HIV and epilepsy
4. To determine the effect of HAART on the safety of antiepileptic agents among Ugandans aged 0-24 years, during 6 months of co-medication with HAART and either carbamazepine or sodium valproate
Secondarily, we shall determine concentrations of the respective antiretroviral agents (efavirenz or lopinavir). The concentrations of the antiretroviral drugs estimated from study 11, will be compared to those obtained in study 1 in an attempt to establish a direct link of the effect of AEDs on the pharmacokinetics of antiretroviral agents. In addition, we shall attempt to evaluate the likelihood of a concentration-dependent effect of efavirenz on the pharmacokinetics and treatment outcomes of antiretroviral agents.
|
Uganda |
2020-09-18 |
2023-09-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Lucas Ampaire
ID:
|
Microbial contamination of locally prepared beverages vended in Kisenyi parish, Kampala: Prevalence, associated factors and utility of rapid diagnostic tests
REFNo: HS586ES
1. To determine the prevalence and factors associated with microbial contamination of locally prepared beverages vended in Kisenyi Parish, Kampala, Uganda.
2. To determine the common contaminating microbial agents in the locally prepared beverages and their antibiotic sensitivity patterns.
3. To assess the performance of MaxSignal® E. coli O157 Strip Test Kit and MaxSignal® Salmonella Strip Test Kit on food-borne pathogens in locally prepared beverages vended in Kisenyi Parish, Kampala , Uganda
4. To develop and evaluate the performance of a local multiplexed strip/cassette for rapid detection of common food contaminants
|
Uganda |
2020-09-18 |
2023-09-18 |
Medical and Health Sciences |
|
Degree Award |
|
Jane Achan Edwin
ID: UNCST-2023-R005498
|
Malaria among patients admitted with COVID-19: a case series
REFNo: HS666ES
General Objective: To understand the burden and clinical consequences of malaria among COVID-19 patients
Specific objectives
1. To determine the prevalence of malaria among patients with COVID-19 and to evaluate the risk of malaria following hospital discharge.
2. To determine the magnitude of previous exposure to malaria among patients with COVID-19
3. To document the impact of malaria on clinical outcomes of patients with COVID-19
4. To assess the potential impact of currently used antimalarial drugs (artemether-lumefantrine and dihydroartemisinin-piperaquine) on clinical outcomes among COVID-19 patients prescribed these drugs as per current clinical indications
5. To document the clinical spectrum of malaria among patients with COVID-19
6. To evaluate the potential interactions between COVID-19 and other infectious diseases including HIV/AIDS and TB
7. To describe health worker perspectives on the management of malaria in COVID-19 patients
|
Uganda |
2020-09-16 |
2023-09-16 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|